Cocoa

drug
On this page

Also known as Cacao minar wholeCacao wholeChocolateTheobroma cacaoTheobroma cacao wholeTheobroma caribaea wholeTheobroma integerrima wholeTheobroma kalagua wholeTheobroma saltzmanniana whole

Summary

Cocoa (CHEMBL2108233) is a phase-3 clinical-stage unknown; indicated across 5 conditions including sleep disorder and peripheral arterial disease.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 5 conditions
  • Clinical trials: 101

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2108233
NameCocoa
TypeUnknown
Max phase3

Also known as: Cacao minar whole, Cacao whole, Chocolate, Cocoa, Theobroma cacao, Theobroma cacao whole, Theobroma caribaea whole, Theobroma integerrima whole, Theobroma kalagua whole, Theobroma saltzmanniana whole, COCOA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
sleep disorder3MONDO:0100081EFO:0008568
peripheral arterial disease3MONDO:0005386EFO:0004265
coronary artery disorder1MONDO:0005010EFO:0001645
hypertensive disorder1MONDO:0005044EFO:0000537

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 101.

Phase distribution

PhaseTrials
Not specified84
PHASE45
PHASE15
PHASE1/PHASE23
PHASE23
PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01314924PHASE4COMPLETEDEffects of Acute Ingestion of Dark Chocolate on Endothelial Function in Hypertensive Patients
NCT02062710PHASE4COMPLETEDAntitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo
NCT02422745PHASE4COMPLETEDCOcoa Supplement and Multivitamin Outcomes Study
NCT03205202PHASE4UNKNOWNCataract and AMD in a Trial of a Multivitamin and Cocoa Extract
NCT05510375PHASE4UNKNOWNCocoa Supplementation, Inflammaging, and Epigenetic Aging
NCT04794530PHASE3RECRUITINGThe COCOA-PAD II Trial
NCT00790465PHASE1/PHASE2UNKNOWNEfficacy of Dark Chocolate in Achalasia Patients
NCT01064583PHASE1/PHASE2COMPLETEDCocoa Flavanols and Painfree Walking Distance
NCT01412320PHASE1/PHASE2COMPLETEDCocoa Flavanols in Renal Disease
NCT01431443PHASE2COMPLETEDConsumption of Chocolate in Pregnant Women.
NCT01444625PHASE2COMPLETEDFlavanols and Skin Photo Protection: a Clinical Trial
NCT01659060PHASE2COMPLETEDChocolate Consumption in Healthy Pregnant Women Trial
NCT00421499PHASE1COMPLETEDEffects of Cocoa Intake on Blood Pressure in Elderly Individuals With Mild Hypertension
NCT00521573PHASE1COMPLETEDEffects of Chocolate on Coronary Vasomotion in Patients After Heart Transplantation
NCT00538083PHASE1COMPLETEDCocoa and Endothelial Function in Adults With Elevated BMI
NCT00553774PHASE1COMPLETEDEffect of Cocoa Flavanols on Vascular Function
NCT00654862PHASE1COMPLETEDAcute Hemodynamic Effects of Cocoa Polyphenols in Subjects With Hypertension and Optimal Blood Pressure
NCT02924857Not specifiedACTIVE_NOT_RECRUITINGThe Chocolate Touch Study
NCT05017051Not specifiedRECRUITINGStudy for the Quantification in Ecological Conditions of Sensorimotor and Dysexecutive Disorders in Cerebral Palsy Patients
NCT05232669Not specifiedACTIVE_NOT_RECRUITINGCOcoa Supplement and Multivitamin Outcomes Study: Effects on Falls and Physical Performance
NCT05755217Not specifiedRECRUITINGRenal Ultrasound Response After Chocolate Consumption
NCT06513052Not specifiedACTIVE_NOT_RECRUITINGFlavanol-rich Cocoa on Digestive and Cerebrovascular Health in the Colombian Adults
NCT06769035Not specifiedACTIVE_NOT_RECRUITINGEffect of a Food Supplement with Natural Extracts of Cocoa, Amaranth Seed and Ginger in Overweight or Obese Patients
NCT06808230Not specifiedRECRUITINGCocoa Extract for Migraine Trial
NCT06808282Not specifiedACTIVE_NOT_RECRUITINGEffects of Dark Chocolate on the Risk Factors of Cardiovascular Diseases
NCT07093346Not specifiedRECRUITINGThe Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT07418151Not specifiedRECRUITINGEffect of Maternal Chocolate Consumption on Fetal Non-Stress Test (NST) Reactivity.
NCT07556627Not specifiedRECRUITINGEffect of Chocolate Consumption Prior to Prolonged Sitting on Cardiovascular Health in Adults
NCT00492713Not specifiedCOMPLETEDPolyphenol Bioavailability From Chocolate
NCT00493519Not specifiedUNKNOWNCephalic Phase in Anorexia Nervosa,Bulimia Nervosa and Obese Binge Eaters
NCT00493740Not specifiedUNKNOWNCephalic Phase of Oncology Patients Before and After Chemotherapy as Compared to Healthy Controls
NCT00513344Not specifiedCOMPLETEDEfficacy of Polyphenols From Milk and Dark Chocolate
NCT00639665Not specifiedCOMPLETEDCocoa, Polyphenols, and the Kidney in Healthy Subjects and in Subjects With Hypertension and Diabetes Mellitus
NCT00825695Not specifiedCOMPLETEDFlavanol-Rich Cocoa and Cerebral Blood Flow
NCT00906763Not specifiedUNKNOWNEffects of Chocolate on Motor Symptoms of Parkinson’s Disease
NCT01099150Not specifiedCOMPLETEDDark Chocolate and Platelet Function in Humans
NCT01259739Not specifiedCOMPLETEDCocoa Flavanols and Exercise Capacity
NCT01344551Not specifiedCOMPLETEDEffects of Cocoa Flavanols on Human Cognitive Function
NCT01481389Not specifiedCOMPLETEDThe Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects
NCT01496235Not specifiedTERMINATEDEffect of Cocoa Consumption in Cardiovascular and Immune Parameters

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).